EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Germline Pathogenic Variants in HER2 ‐Positive Breast Cancer: Spectrum and Clinical Implications in a High‐Risk Chinese Cohort

Lijia Zhou, Mengqian Ni, Anli Yang, Qingru Zhou, Daining Wang, Shu Dun, Fei Xu, Jiajia Huang, Xiwen Bi iD, Wen Xia, Ruoxi Hong, Qiufan Zheng und 9 weitere

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.05.2026. Verfasst von Lijia Zhou und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen Uni…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Germ-Line Mutation, Biomarkers, Tumor. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

H ereditary cancer risk assessment has predominantly focused on HER2‐negative breast cancer (BC), with limited characterization of germline pathogenic variants (GPVs) in HER2‐positive disease. This study aimed to delineate the prevalence, clinicopathological correlates, and clinical implications of GPVs in a cohort of HER2‐positive BC patients.

Methods

We retrospectively reviewed BC patients who had undergone genetic testing at the Sun Yat‐sen University Cancer Center from 2014 to 2024. GPV profiles, clinicopathological features, and survival outcomes were compared between HER2‐positive and HER2‐negative patients, with additional stratified analysis in HER2‐positive GPV carriers.

Results

Among 1692 BC patients, 1,499 patients met NCCN high‐risk criteria. In multigene panel testing, GPVs were identified in 18.1% (52/288) of HER2‐positive BC and 22.4% (269/1,201) of HER2‐negative BC patients. HER2‐positive GPV carriers exhibited distinct molecular profiles, with higher frequencies of BRCA2 (23/52, 44.2%) and TP53 (14/52, 26.9%) mutations and a lower BRCA1 prevalence (6/52, 11.5%) compared to HER2‐negative carriers ( BRCA2 : 106/269, 37.9%; TP53 : 9/269, 3.3%; BRCA1 : 117/269, 43.5%). Clinically, HER2‐positive carriers were diagnosed at a younger median age, had higher hormone receptor (HR) positivity, and less frequently reported a family history of BRCA ‐related cancers. GPVs were not associated with increased locoregional recurrence or distant metastasis in HER2‐positive BC but significantly elevated the risk of contralateral BC and other secondary primary cancers—a risk particularly pronounced in TP53 carriers.

Conclusions

HER2‐positive BC patients harbored a distinct GPV spectrum compared to HER2‐negative patients. While GPVs did not worsen primary BC‐specific outcomes, they conferred a significantly increased risk of second primary cancers, underscoring the clinical utility of multigene panel testing for comprehensive risk stratification and long‐term management in this population. Study Limitations This retrospective, single‐center study comprised a clinically enriched high‐risk cohort, which may limit the generalizability of prevalence estimates. The extended inclusion period and evolving classification standards, despite reannotation, represent inherent methodological constraints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesGerm-Line MutationBiomarkers, TumorHumansFemaleMiddle AgedRetrospective StudiesAdultGenetic Predisposition to DiseaseChinaAgedGenetic TestingEast Asian People

Stichwörter der Autor:innen

BRCA1/2 genesHER2‐positivehereditary breast cancermultigene panel testingnon‐BRCA genes

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
  • Department of Breast Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.
  • Department of Molecular Diagnostics, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.

ORCID-Profile: Xiwen Bi, Jun Tang, Zhongyu Yuan, Fang Wang

Zitieren

APA

Zhou, L., Ni, M., Yang, A., Zhou, Q., Wang, D., Dun, S., Xu, F., Huang, J., Bi, X., Xia, W., Hong, R., Zheng, Q., Chen, M., Jiang, K., Tang, J., Wang, X., Yuan, Z., Wang, S., Shi, Y., …, & An, X. (2026). Germline Pathogenic Variants in HER2 ‐Positive Breast Cancer: Spectrum and Clinical Implications in a High‐Risk Chinese Cohort. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71865

Vancouver

Zhou L, Ni M, Yang A, Zhou Q, Wang D, Dun S, et al. Germline Pathogenic Variants in HER2 ‐Positive Breast Cancer: Spectrum and Clinical Implications in a High‐Risk Chinese Cohort. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71865

BibTeX
@article{Zhou2026,
  author = {Zhou, Lijia and Ni, Mengqian and Yang, Anli and Zhou, Qingru and Wang, Daining and Dun, Shu and Xu, Fei and Huang, Jiajia and Bi, Xiwen and Xia, Wen and Hong, Ruoxi and Zheng, Qiufan and Chen, Meiting and Jiang, Kuikui and Tang, Jun and Wang, Xi and Yuan, Zhongyu and Wang, Shusen and Shi, Yanxia and Wang, Fang and An, Xin},
  title = {Germline Pathogenic Variants in HER2 ‐Positive Breast Cancer: Spectrum and Clinical Implications in a High‐Risk Chinese Cohort},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71865}
}
Kostenlos starten →